ipilimumab/nivolumab for favorable-risk mrcc
Published 4 years ago • 147 plays • Length 7:03Download video MP4
Download video MP3
Similar videos
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
3:16
optimizing the use of ipilimumab/nivolumab in mrcc
-
7:36
mrcc patient selection for ipilimumab/nivolumab
-
6:16
treatment-free survival results of nivolumab and salvage nivolumab ipilimumab for accrcc
-
3:07
checkmate-214: nivolumab/ipilimumab for mrcc?
-
2:08
nivolumab with ipilimumab for mrcc
-
2:00
nivolumab and ipilimumab in mrcc
-
1:34
fda approval of frontline nivolumab/ipilimumab combo in rcc
-
0:51
dr. pal on the frontline approval of nivolumab and ipilimumab in mrcc
-
8:26
front-line therapy with nivolumab and salvage nivolumab ipilimumab in patients with advanced rcc
-
7:43
deferred therapy for favorable-risk mrcc patients
-
5:44
hcrn-gu16-260: nivolumab and salvage nivolumab-ipilimumab in patients with advanced rcc
-
8:40
favorable-risk mrcc: choosing appropriate frontline therapy
-
1:47
dr. harrison on the possibility of nivolumab plus ipilimumab becoming the new il-2
-
5:52
nivolumab and salvage nivolumab plus ipilimumab for arcc
-
11:58
checkmate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma
-
3:54
treating intermediate and favorable-risk renal cell carcinoma
-
1:30
targeted therapies for the treatment of mrcc after nivolumab-ipilimumab failure